Miscellaneous
Non-alcoholic steatohepatitis (NASH) is a growing concern for all patients with metabolic disease. This liver disease is an advanced form of fatty liver disease, recently renamed to metabolic-associated fatty liver disease (MAFLD), which is present in up to 90% of people with obesity, type 2 diabetes or metabolic syndrome. As 20% of people with MAFLD will progress to NASH, this is an important subset of patients, and a common comorbidity to consider. Join Professor WIlliam Alazawi for a summary of how to identify and manage NASH among people with diabetes. References: Anstee QM, et al. Nat Rev Gastroenterol Hepatol. 10(6):330-44. Ciardullo S, et al. Open Diabetes Research and Care. 2020;8:e000904. EASL-EASD-EASO. J Hepatol. 2016; 64(6):1388-1402 Eslam M, et al. J Hepatol. 73(1):202-209. Jennison E, et al. Postgraduate Medical Journal 2019;95:314-322. Perumpail BJ, et al. World J Gastroenterol. 21;23(47):8263-8276. This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.